Clinical trials: Aggressive Behaviour
CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma
Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy…
- Trial name
- NCT01933711
- Testing
- rituximab
- Where
- 3 sites in Germany
- Volunteers
- 328 people
- Sponsor
- University Hospital Heidelberg
Aggression
Cognitive Behavioral Aggression Treatment
Aggressive behavior is a leading worldwide public health problem. Despite this, relatively little is known about how to best treat individuals who are highly angry and aggressive.
- Trial name
- NCT01264900
- Testing
- Psychotherapy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Temple University
Desmoplastic Small Round Cell Tumor, Synovial Sarcoma
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
PAMSARC is a non-commercial interventional Phase 2 clinical trial of academic research institutions, with its primary goal being to improve medical treatment of fusion driven Desmoplastic small round cell tumor (DSRCT) and…
- Trial name
- PAMSARC (NCT06456359)
- Testing
- Signifor
- Where
- 4 sites in Germany
- Volunteers
- 28 people
- Sponsor
- University Hospital Heidelberg
Non-hodgkin's Lymphoma
Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma
Primary Outcome Measures: Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ] Secondary Outcome Measures: The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days…
- Trial name
- NCT03456466
- Testing
- TQB2303, Rituximab
- Where
- 2 sites in China
- Volunteers
- 122 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL.
- Trial name
- ELM-1 (NCT02290951)
- Testing
- Odronextamab multiple dose levels
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 200 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Sclerosis
Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course
Chart review.
- Trial name
- NCT02301572
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Sclerosis, Relapsing-Remitting
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun.
- Trial name
- TREAT-MS (NCT03500328)
- Testing
- Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
- Where
- 47 sites in United States
- Volunteers
- 900 people
- Sponsor
- Johns Hopkins University
Cyberbullying
Cyberbullying, Empathy, and Storytelling in Adolescents
This randomized controlled experimental study examined the effect of a storytelling intervention on cyberbullying and empathy levels in adolescents.
- Trial name
- NCT06508736
- Testing
- Storytelling
- Where
- Turkey (Türkiye)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Gazi University
Suicide, Suicidal
CAMPUS Expanded "Classification and Assessment of Mental Health Performance Using Semantics Expanded"
Open enrollment study to collect data for the optimization of machine learning models for use in an app for the early detection of mental health and suicidal risk.
- Conditions
- Suicide, Suicidal, Suicide, Attempted, Suicidal Ideation
- Trial name
- CAMPUS-E (NCT04493736)
- Testing
- MHSAFE app recording
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Clarigent Health
Coronary Artery Disease
Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)
The purpose of this study is to evaluate the prevention of cardiovascular disease by moderate cholesterol lowering therapy, pitavastatin 1mg/day or aggressive cholesterol lowering therapy, pitavastatin 4mg/day in patients with…
- Trial name
- NCT01042730
- Testing
- Pitavastatin 1 mg daily or 4 mg daily
- Where
- 2 sites in Japan
- Volunteers
- 13,054 people
- Sponsor
- Juntendo University
Non-Hodgkin Lymphoma
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of…
- Trial name
- BELINDA (NCT03570892)
- Testing
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Novartis Pharmaceuticals
Violence, Bullying
A Stage-Based Expert System for Teen Dating Violence Prevention
Male-to-female intimate partner violence accounts for 26% of violence-related injuries in women presenting in hospital emergency departments and 33% of all female homicides.
- Trial name
- NCT02458365
- Testing
- Teen Choices: A Program for Healthy Nonviolent Relationships, Health In Motion
- Volunteers
- 3,901 people, healthy volunteers welcome
- Sponsor
- Pro-Change Behavior Systems
Autism, Intellectual Disability
Cognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability
In addition to the core symptoms, children and adolescents with Autism Spectrum Disorder (ASD) often exhibit disruptive behavior problems including irritability, tantrums, noncompliance, and aggression.
- Trial name
- NCT02914951
- Testing
- Cognitive-Behavioral Therapy, Functional magnetic resonance imaging (fMRI)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Yale University
Lymphoma, Non-Hodgkin
Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Aggressive non-Hodgkin's lymphoma is difficult to handle once it relapses or becomes refractory to chemotherapy. Various second or third line chemotherapies, which are called salvage chemotherapy, were developed without promising…
- Trial name
- NCT00367497
- Testing
- Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin
- Where
- Japan
- Volunteers
- 5 people
- Sponsor
- Keio University
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA)…
- Trial name
- CATCH-177 (NCT06738303)
- Testing
- Cabazitaxel and carboplatin, Lu-PSMA-617
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Anger, Aggression
The Peace of Mind and Body Project: Treatment Development of Yoga for Anger Management in Incarcerated Adults
The investigators will conduct a pilot randomized clinical trial (n = 40) of hatha yoga vs. a health education group (attention control) for prisoners high in self-reported anger dysregulation.
- Trial name
- POMB (NCT05336123)
- Testing
- Hatha Yoga, Health Education
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brown University
End Stage Renal Disease
ENhancing Maturation of Autogenous Arteriovenous Hemodialysis Access by Aggressive surveillaNCe With Duplex and Endovascular Treatment
The aim of this study is to evaluate whether Aggressive duplex surveillance after vascular access surgery with native vein for hemodialysis can increase the maturation rate of arteriovenous fistula.
- Trial name
- ENHANCE (NCT01597115)
- Testing
- Duplex ultrasonography
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National University Hospital
Violent Aggressive Behavior, Mediation
Impact of a Mediator for Patient Intake in Emergency Departments
Violence in the workplace is becoming a serious phenomenon in the contemporary world of work. Hospital staff, like any employee working in contact with the public, is particularly exposed to this violence.
- Trial name
- MEDIA (NCT03139110)
- Testing
- Presence of a mediator in the emergency departments
- Where
- 4 sites in France
- Volunteers
- 2,378 people
- Sponsor
- Hospices Civils de Lyon
Schizophrenia, Cognitive Deficits
Can Cognitive Training Decrease Reactive Aggression?
The purpose of the study is to examine the effects of cognitive training on emotion regulation, impulse control, and aggression in people with schizophrenia.
- Conditions
- Schizophrenia, Cognitive Deficits, Impulsive Aggression, Emotion
- Trial name
- NCT03623477
- Testing
- Cognitive Remediation (CRT), CRT+ Social Cognition Training
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Weill Medical College of Cornell University
Relapsed/Refractory Aggressive B-cell Lymphomas
Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy.
- Trial name
- NCT02271945
- Testing
- MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- MedImmune LLC